Most older adults using cannabis report initiating use after the age of 60 years primarily to treat pain.
The number of Waddell signs present may indicate future treatment failure.
About half of waivered clinicians prescribe buprenorphine for opioid use disorder and most treat at levels below their patient limits.
The percentage of those receiving opioid prescriptions following arthroplasty has increased.
Orphengesic Forte for the symptomatic relief of mild to moderate pain of acute musculoskeletal disorders is now available.
A targeted program that allows all prescribers to access real-time data and track and compare their own performance with those of others can improve compliance with opioid prescribing guidelines.
The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.
From 2005 to 2016, skeletal muscle relaxant (SMR) use increased in the United States.
In 2015 to 2018, 10.7% of US adults aged 20 years or older used one or more prescription pain medications.
For patients with chronic low back pain, tanezumab 10 mg significantly improves pain and function.